Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery

This review looks at two studies, NCT02472353 and NCT02236806, which are expected to provide novel insights into our understanding of treatment for cardiac toxicity caused by neoadjuvant targeted therapy in breast cancer patients. Current prevention and treatment strategies are assessed, with a recommendation that future research should focus on the cardiovascular safety of patients with impaired baseline cardiac function receiving targeted therapy, with an emphasis on the development of more sensitive cardiac function assays and more aggressive cardiovascular interventions during cancer treatment.